How Does Interferon Work? Mechanism of Action, Per the Research

The short answer from the literature

Interferons are not a single molecule but a family of secreted signalling proteins. Published pharmacology describes a consistent core mechanism: an interferon binds a specific pair of transmembrane receptor chains, receptor-associated Janus kinases become active, those kinases phosphorylate signal transducer and activator of transcription (STAT) proteins, and the phosphorylated STAT complexes enter the nucleus and bind defined DNA elements to switch on hundreds of interferon-stimulated genes (ISGs). A 2005 review in Nature Reviews Immunology set out this framework for both type I and type II interferon signalling, describing the receptor chains, the associated kinases and the distinct transcription factor complexes each receptor system assembles (PMID 15864272).

Everything that follows separates what the literature treats as established mechanism (receptor identity, kinase coupling, transcription factor assembly) from proposed or context-dependent mechanism (condensate formation, tumour-intrinsic resistance programmes, disease-specific amplification loops), and labels cell-culture and animal work as such.

For a broader orientation to this cytokine family, see the interferon overview.

Receptor targets: where interferons bind

The 2005 review described type I interferons — a group that includes the IFN-alpha subtypes and IFN-beta — as binding a heterodimeric receptor made of IFNAR1 and IFNAR2, while type II interferon (IFN-gamma) binds a separate receptor assembled from IFNGR1 and IFNGR2 chains (PMID 15864272). The same review described the receptor chains as having no intrinsic enzymatic activity of their own; instead they are pre-associated with Janus-family tyrosine kinases that are brought together when the ligand cross-links the two chains (PMID 15864272).

The papers assembled for this page concern type I and type II interferon signalling; claims about other interferon classes are therefore not made here.

The canonical JAK–STAT pathway, step by step

Type I interferon

The 2005 review described type I interferon engagement of IFNAR1 and IFNAR2 as activating TYK2 and JAK1, which phosphorylate STAT1 and STAT2; the phosphorylated STATs then associate with interferon regulatory factor 9 (IRF9) to form the trimeric ISGF3 complex, which binds interferon-stimulated response elements in the promoters of antiviral and immunoregulatory genes (PMID 15864272). The same review noted that type I interferon receptors can also recruit additional STAT family members and non-STAT pathways depending on cell type, which is one reason the output of the pathway is not uniform across tissues (PMID 15864272).

Type II interferon

For IFN-gamma, the review described JAK1 and JAK2 activation downstream of IFNGR1/IFNGR2 and the formation of STAT1 homodimers (sometimes termed GAF) that bind gamma-activated sequence elements, producing a gene programme that overlaps with, but is not identical to, the type I programme (PMID 15864272).

What triggers interferon production in the first place

Receptor signalling is only half of the mechanism; something must induce the interferon. A large body of work has focused on cytosolic DNA sensing. A 2020 review in Nature Reviews Molecular Cell Biology described cyclic GMP–AMP synthase (cGAS) binding double-stranded DNA in the cytosol and synthesising the second messenger 2'3'-cGAMP, which activates the endoplasmic reticulum adaptor STING and leads to TBK1-dependent phosphorylation of IRF3 and transcription of type I interferon genes (PMID 32424334). A 2019 review in Nature Reviews Genetics described the same sensing axis as a mechanism by which microbial DNA, as well as self-DNA released from damaged mitochondria or nuclei, can initiate interferon responses in health and disease (PMID 31358977).

A 2025 review in Nature Reviews Immunology emphasised that cGAS–STING output is not limited to interferon transcription, describing a diversity of cellular outcomes — including inflammatory gene expression, autophagy and cell-death programmes — that depend on signal strength and cellular context (PMID 39774812). This is an important nuance: the same upstream sensor does not always produce the same downstream physiology.

Phase separation as a proposed organising principle

A 2022 review in Nature Reviews Immunology described biomolecular condensate formation — liquid–liquid phase separation — as a mechanism that concentrates immune signalling components, including DNA-sensing machinery, into membraneless compartments that can raise local signalling efficiency (PMID 34230650). This is best read as a biophysical organising principle described largely from reconstituted and cell-based systems rather than as a validated therapeutic target.

Downstream physiology: what the interferon-stimulated gene programme does

ADP-ribosylation enzymes

Several ISGs are themselves enzymes that modify other proteins. A 2024 study in The EMBO Journal reported that PARP14 and the PARP9/DTX3L complex regulate interferon-induced ADP-ribosylation, describing opposing writer and eraser-associated activities that shape the modification landscape after interferon exposure in cultured cells (PMID 38834853). Researchers framed this as a post-translational layer sitting downstream of transcription, meaning interferon output is tuned by protein modification as well as by gene induction (PMID 38834853).

Immune checkpoint ligands

Interferon signalling also induces ligands that restrain T cells. A 2017 study in Cell Reports reported that interferon receptor signalling through JAK and STAT proteins, with a contribution from IRF1, drove expression of the checkpoint ligands PD-L1 and PD-L2 in tumour cell lines (PMID 28494868). That work was performed in vitro; the study described the receptor-to-promoter wiring rather than a clinical outcome (PMID 28494868).

Sustained versus acute signalling

A 2016 study in Cell reported that sustained tumour interferon signalling was associated with a multigenic resistance programme to immune checkpoint blockade in preclinical tumour models, distinguishing the acute antitumour effects of interferon from the consequences of chronic pathway activation (PMID 27912061). Researchers in that work used animal and cell-based tumour systems, so the findings describe mechanism in models rather than a treatment outcome in people (PMID 27912061).

Upstream metabolic gating

A 2024 study in Nature reported that glycosphingolipid synthesis mediated immune evasion in KRAS-driven cancer models, linking a lipid biosynthetic route to the strength of interferon-associated immune recognition (PMID 39112706). That study was conducted in cancer models and cell systems, and the mechanism is best described as context-dependent rather than general (PMID 39112706).

How the signal is tuned and terminated

Interferon responses are self-limiting by design. A 2024 study in Cell reported that exonization of transposable element sequences contributed to the regulation of human interferon signalling, describing how sequences captured into transcripts generated alternative products that altered pathway output in human cells (PMID 39672162). Researchers positioned this as a species-specific regulatory layer, which is one reason findings from rodent interferon biology do not always transfer directly to human cells (PMID 39672162).

At the level of the sensor, the 2025 review described multiple regulatory checkpoints on cGAS–STING — including post-translational modification, trafficking and degradation of STING — that limit how long an interferon-inducing signal persists (PMID 39774812).

Established mechanism versus proposed mechanism

When the Pathway Is Dysregulated: What Studies Report

Because interferon signalling is inflammatory by nature, the literature pays close attention to what happens when it is not switched off. A 2025 study in Nature reported that loss-of-function mutations in PLD4, a nuclease implicated in degrading nucleic acids, led to systemic lupus erythematosus, a disease in which nucleic-acid sensing and interferon-associated inflammation feature prominently (PMID 40931063). A 2019 review similarly described cGAS–STING-driven DNA sensing as contributing to autoinflammatory and interferonopathy phenotypes as well as to antimicrobial defence (PMID 31358977).

Organ-level consequences have also been reviewed. A 2021 review in JHEP Reports described cGAS–STING signalling as participating in liver disease processes, including inflammatory and fibrotic contexts, summarising mechanistic work largely from animal models and human tissue analyses (PMID 34381984). None of these papers describe adverse events of an administered product; they describe what excess or mistimed pathway activity does in biological systems (PMID 34381984, PMID 40931063).

Limits of the mechanistic evidence

• Much of the detailed wiring described above came from cell-culture systems and genetically modified animals, including the checkpoint-ligand work (PMID 28494868) and the tumour resistance programme work (PMID 27912061).
• Pathway output is context-dependent: the same sensor can drive transcription, autophagy or cell death depending on conditions (PMID 39774812).
• Human-specific regulatory elements mean cross-species extrapolation is imperfect (PMID 39672162).
• Mechanism describes how a signal propagates, not whether any particular intervention is safe or effective in people.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or therapy. It summarises what published studies and reviews reported about interferon signalling mechanism and does not describe dosing, administration or expected results.

References

• Mechanisms of type-I- and type-II-interferon-mediated signalling (Nature Reviews Immunology, 2005)
• Molecular mechanisms and cellular functions of cGAS-STING signalling (Nature Reviews Molecular Cell Biology, 2020)
• DNA sensing by the cGAS-STING pathway in health and disease (Nature Reviews Genetics, 2019)
• Regulation of cGAS-STING signalling and its diversity of cellular outcomes (Nature Reviews Immunology, 2025)
• Phase separation in immune signalling (Nature Reviews Immunology, 2022)
• PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation (The EMBO Journal, 2024)
• Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression (Cell Reports, 2017)
• Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade (Cell, 2016)
• Regulation of human interferon signaling by transposon exonization (Cell, 2024)
• Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer (Nature, 2024)
• Loss-of-function mutations in PLD4 lead to systemic lupus erythematosus (Nature, 2025)
• The role of cGAS-STING signalling in liver diseases (JHEP Reports, 2021)